GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protalix BioTherapeutics Inc (FRA:PBDA) » Definitions » Shiller PE Ratio

Protalix BioTherapeutics (FRA:PBDA) Shiller PE Ratio : (As of Jul. 24, 2025)


View and export this data going back to 2008. Start your Free Trial

What is Protalix BioTherapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Protalix BioTherapeutics Shiller PE Ratio Historical Data

The historical data trend for Protalix BioTherapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protalix BioTherapeutics Shiller PE Ratio Chart

Protalix BioTherapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Protalix BioTherapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Protalix BioTherapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Protalix BioTherapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protalix BioTherapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Protalix BioTherapeutics's Shiller PE Ratio falls into.


;
;

Protalix BioTherapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Protalix BioTherapeutics's E10 for the quarter that ended in Mar. 2025 is calculated as:

For example, Protalix BioTherapeutics's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.046/134.9266*134.9266
=-0.046

Current CPI (Mar. 2025) = 134.9266.

Protalix BioTherapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201506 -0.445 100.684 -0.596
201509 -0.356 100.392 -0.478
201512 7.069 99.792 9.558
201603 -0.808 100.470 -1.085
201606 -0.979 101.688 -1.299
201609 -0.624 101.861 -0.827
201612 -0.190 101.863 -0.252
201703 -4.488 102.862 -5.887
201706 -0.534 103.349 -0.697
201709 -0.755 104.136 -0.978
201712 -0.735 104.011 -0.953
201803 -0.405 105.290 -0.519
201806 -0.514 106.317 -0.652
201809 -0.343 106.507 -0.435
201812 -0.352 105.998 -0.448
201903 -0.443 107.251 -0.557
201906 -0.460 108.070 -0.574
201909 -0.218 108.329 -0.272
201912 0.018 108.420 0.022
202003 0.090 108.902 0.112
202006 -0.115 108.767 -0.143
202009 -0.119 109.815 -0.146
202012 0.025 109.897 0.031
202103 -0.118 111.754 -0.142
202106 -0.208 114.631 -0.245
202109 -0.077 115.734 -0.090
202112 -0.124 117.630 -0.142
202203 -0.045 121.301 -0.050
202206 -0.104 125.017 -0.112
202209 -0.071 125.227 -0.076
202212 -0.066 125.222 -0.071
202303 -0.047 127.348 -0.050
202306 0.194 128.729 0.203
202309 -0.037 129.860 -0.038
202312 -0.092 129.419 -0.096
202403 -0.055 131.776 -0.056
202406 -0.028 132.554 -0.029
202409 0.027 133.029 0.027
202412 0.086 133.157 0.087
202503 -0.046 134.927 -0.046

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Protalix BioTherapeutics  (FRA:PBDA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Protalix BioTherapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Protalix BioTherapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Protalix BioTherapeutics Business Description

Traded in Other Exchanges
Address
2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Protalix BioTherapeutics Headlines

No Headlines